Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pazopanib · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm A: FLO + Pazopanib | EXPERIMENTAL | - |
| Arm B: FLO | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Pazopanib | DRUG | Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression |
| 5-FU, Oxaliplatin, Leukovorin (FLO) | DRUG | Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles |
Inclusion Criteria: * Subjects must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow up. * Age ≥ 18 years. * Histologically confirmed adenocarcinoma of the stomach or the gastroesophageal junct...
Top 20 of 44 competitors